Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | SRZN |
---|---|---|
09:57 ET | 5000 | 9.917 |
10:06 ET | 929 | 8.78 |
10:09 ET | 100 | 9.1842 |
11:09 ET | 100 | 8.85 |
11:25 ET | 100 | 8.81 |
11:32 ET | 100 | 8.995 |
01:18 ET | 100 | 8.9 |
01:56 ET | 100 | 8.96 |
02:39 ET | 100 | 8.9926 |
04:00 ET | 342 | 9.15 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Surrozen Inc | 30.2M | -0.5x | --- |
ALT5 Sigma Corp | 30.2M | -0.6x | --- |
Impact Biomedical Inc | 30.1M | -12.5x | --- |
Chemomab Therapeutics Ltd | 29.6M | -1.7x | --- |
ProMIS Neurosciences Inc | 31.2M | -5.3x | --- |
RenovoRx Inc | 29.0M | -2.3x | --- |
Surrozen, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a range of organs and tissues. The Company is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with a current focus on severe liver and eye diseases. Its two lead product candidates include SZN-043 and SZN-413. SZN-043 is the first development candidate using Surrozen’s SWEETS technology. It is developing SZN-043 for severe liver diseases, initially focusing on alcohol-associated hepatitis. It has completed Phase I a clinical trial in patients with chronic liver disease and healthy volunteers. SZN-413 is a bi-specific antibody targeting Fzd4-mediated Wnt signaling designed using Surrozen’s SWAP technology. SZN-413 is being developed for the treatment of retinal vascular-associated diseases.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $30.2M |
---|---|
Revenue (TTM) | $10.0M |
Shares Outstanding | 3.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.82 |
EPS | $-17.05 |
Book Value | $18.39 |
P/E Ratio | -0.5x |
Price/Sales (TTM) | 3.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -266.71% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.